

Table S1. Clinical and demographic characteristics of patients, overall and by the presence of *Leishmania* infection

	Overall (n=120)	<i>Leishmania</i> -no (n=70)	<i>Leishmania</i> -yes (n=50)	P
Donor age, years	51.9±13.9	51.3±13.6	52.8±14.4	0.559
Recipient age, years	58.6±15.6	57.5±15.9	58.9±15.5	0.448
Male gender, %	64.2	62.9	66.0	0.723
Dialysis before Tx, %	91.6	91.3	92.0	0.893
Diabetes, %	10.8	12.9	8.0	0.399
Previous CV events, %	27.2	29.9	23.4	0.446
Deceased (vs. living) donor, %	77.5	77.1	78.0	0.912
Geographical distribution,				0.706
Northern Italy	68.3	59.8	40.2	
Central Italy	16.7	50.0	50.0	
Southern Italy	15.0	61.1	38.9	
Renal diagnosis, %				0.411
Hypertensive nephropathy	5.0	66.7	33.3	
Diabetic nephropathy	4.2	80.0	20.0	
Glomerulonephritis	33.3	57.5	42.5	
Polycystic kidney disease	17.5	47.6	52.4	
Tubulo-interstitial disease	3.3	100	0	
Other/unknown	36.7	56.8	43.2	
Underlying autoimmune disease*	33.3	32.9	34.0	0.896
Hemoglobin, g/dL	11.7±1.6	11.6±1.7	11.7±1.5	0.868
Creatinine, mg/dL	7.8±3.3	7.5±3.2	8.2±3.5	0.284

Leishmania-no; controls, *Leishmania*-yes; asymptomatic *Leishmania* infection, Tx; transplant, CV; cardiovascular. *; n=10 out of 40 patients with autoimmune diseases were treated with immunosuppressants, n=23 out of 40 were not treated with immunosuppressant, while this information was not available for n=7 patients. Comparison among risk categories for *Leishmania* infection (positive vs. negative) was assessed by unpaired Student's t-test or Kruskal-Wallis test, depending on variable distribution. Categorical variables were analyzed using Chi-square test.

Table S2. Performance of single and combined tests in identifying asymptomatic *Leishmania* infection

	WB	WBA	PCR
Alone	Sens 48% NPV 73%	Sens 65% NPV 79%	Sens 8% NPV 60%
With PCR	Sens 54% NPV 75%	Sens 68% NPV 81%	----
With WBA	Sens 98% NPV 99%	----	----

WB, Western blot; WBA, whole blood assay; Sens, sensitivity; NPV, negative predictive value.




Figure S1. Whole blood assay for screening of *Leishmania* infection in patients undergoing kidney transplant. (a) Levels of interleukin-2 (IL-2) and Interferon inducible protein-10 (IP-10) after stimulation of whole blood with soluble *Leishmania* antigen (SLA) in kidney transplant candidates (n=111). Results for each cytokine were reported as the difference between SLA-stimulated and control plasma concentrations. The cut-off values for IL-2 and IP-10 were determined by calculating the area under the receiver operating characteristic curve plus the 95% confidence

interval and were 21.9 pg/mL for IL-2 and 762.5 pg/ml for IP-10, respectively. AS; patients with asymptomatic *Leishmania* infection, NC; patients without asymptomatic *Leishmania* infection. **** $p \leq 0.0001$ by non-parametric Mann-Whitney U test. **(b)** Different release of soluble mediators upon SLA stimulation of peripheral blood in patients testing positive to the whole blood assay (n=32). The overlap between the positive results for IL-2 and IP-10 is represented by the shared region in the diagram.